Close Menu

NEW YORK – Oncocyte said Thursday that it has agreed to enter a licensing and collaboration agreement with Chronix Biomedical.

Under the agreement, Oncocyte is licensing Chronix's patented technology for blood-based copy number instability testing. In turn, Chronix will use its laboratory network in Germany to accelerate the EU market commercial launch of Oncocyte's DetermaRx.

Financial terms of the deal were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The UK and the European Union have come to a sticking point in the negotiation of how the UK might remain involved in the Horizon Europe research program, the Guardian reports.

The New York Times reports that experts pushed during a meeting of an FDA advisory board for the agency to require more safety data from SARS-CoV-2 vaccine trials.

The Washington Post reports Moderna expects that it will have enough data on its candidate SARS-CoV-2 vaccine to submit to regulatory authorities by mid-November.

In Science this week: ANXA11 variants affect calcium homeostasis and stress granule disassembly in ALS, and more.